HIV wasting syndrome: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Howard C. Berkowitz
No edit summary
imported>Robert Badgett
No edit summary
Line 1: Line 1:
{{subpages}}
{{subpages}}
According to ''Medical Subject Headings'', '''HIV wasting syndrome''', also called '''AIDS wasting syndrome''', is defined by involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhea or fatigue for more than 30 days in the absence of a defined cause other than [[human immunodeficiency virus]] infection. A constant feature is major muscle wasting with scattered myofiber degeneration. A variety of etiologies, which vary among patients, contributes to this syndrome.
According to ''Medical Subject Headings'', '''HIV wasting syndrome''', also called '''AIDS wasting syndrome''', is a complication of [[Acquired Immune Deficiency Syndrome]] that is defined as "involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhea or fatigue for more than 30 days in the absence of a defined cause other than [[human immunodeficiency virus]] infection. A constant feature is major muscle wasting with scattered myofiber degeneration. A variety of etiologies, which vary among patients, contributes to this syndrome."<ref>{{MeSH}}</ref>


In men, it is associated with [[hypogonadism]] and has been treated with supplemental [[androgen]]s. <ref>{{citation
In men, it is associated with [[hypogonadism]] and has been treated with [[androgen]]s and [[anabolic agent]]s.<ref name="pmid16235407">{{cite journal| author=Johns K, Beddall MJ, Corrin RC| title=Anabolic steroids for the treatment of weight loss in HIV-infected individuals. | journal=Cochrane Database Syst Rev | year= 2005 | volume=  | issue= 4 | pages= CD005483 | pmid=16235407
  | title = Effects of Androgen Administration in Men with the AIDS Wasting Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=16235407 | doi=10.1002/14651858.CD005483 }} </ref><ref>{{citation  | title = Effects of Androgen Administration in Men with the AIDS Wasting Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial | author = Grinspoon, S. ''et al.''  | date = 1 July 1998| volume=129 | issue=1 |  pages=18-26 | journal = Annals of Internal Medicine | url = http://www.annals.org/cgi/content/full/129/1/18?ck=nck}}</ref>  Low androgen levels also have been observed in women, and clinical trials of testosterone patches have shown promise. <ref>{{citation
| author = Grinspoon, S. ''et al.''
  | journal = Journal of Clinical Endocrinology & Metabolism  | volume= 83 | date = August 1983
  | date = 1 July 1998  
  | issue = 8 | pages = 2717-2725 | title = Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study | author = Miller, K. ''et al.'' | http://jcem.endojournals.org/cgi/content/full/83/8/2717|http://jcem.endojournals.org/cgi/content/full/83/8/271}}</ref> A [[systematic review]] by the [[Cochrane Collaboration]] concluded "these results suggest that anabolic steroids may be useful in the treatment of weight loss in HIV infected individuals, due to limitations, treatment recommendations cannot be made."<ref name="pmid16235407">{{cite journal| author=Johns K, Beddall MJ, Corrin RC| title=Anabolic steroids for the treatment of weight loss in HIV-infected individuals. | journal=Cochrane Database Syst Rev | year= 2005 | volume=  | issue= 4 | pages= CD005483 | pmid=16235407
| volume=129  
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=16235407 | doi=10.1002/14651858.CD005483 }} </ref>
| issue=1 |  pages=18-26
| journal = Annals of Internal Medicine | url = http://www.annals.org/cgi/content/full/129/1/18?ck=nck}}</ref>  Low androgen levels also have been observed in women, and clinical trials of testosterone patches have shown promise. <ref>{{citation
  | journal = Journal of Clinical Endocrinology & Metabolism  
  | volume= 83
| date = August 1983
  | issue = 8 | pages = 2717-2725
| title = Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study
| author = Miller, K. ''et al.''
| http://jcem.endojournals.org/cgi/content/full/83/8/2717|http://jcem.endojournals.org/cgi/content/full/83/8/271}}</ref>


There is considerable interest in the use of [[marijuana]] for the syndrome, and there is substantial use outside formal trials. It has been difficult, however, to get approval for trials.
There is considerable interest in the use of [[marijuana]] for the syndrome, and there is substantial use outside formal trials. It has been difficult, however, to get approval for trials.

Revision as of 10:01, 2 April 2010

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

According to Medical Subject Headings, HIV wasting syndrome, also called AIDS wasting syndrome, is a complication of Acquired Immune Deficiency Syndrome that is defined as "involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhea or fatigue for more than 30 days in the absence of a defined cause other than human immunodeficiency virus infection. A constant feature is major muscle wasting with scattered myofiber degeneration. A variety of etiologies, which vary among patients, contributes to this syndrome."[1]

In men, it is associated with hypogonadism and has been treated with androgens and anabolic agents.[2][3] Low androgen levels also have been observed in women, and clinical trials of testosterone patches have shown promise. [4] A systematic review by the Cochrane Collaboration concluded "these results suggest that anabolic steroids may be useful in the treatment of weight loss in HIV infected individuals, due to limitations, treatment recommendations cannot be made."[2]

There is considerable interest in the use of marijuana for the syndrome, and there is substantial use outside formal trials. It has been difficult, however, to get approval for trials.

References

  1. Anonymous (2024), HIV wasting syndrome (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. 2.0 2.1 Johns K, Beddall MJ, Corrin RC (2005). "Anabolic steroids for the treatment of weight loss in HIV-infected individuals.". Cochrane Database Syst Rev (4): CD005483. DOI:10.1002/14651858.CD005483. PMID 16235407. Research Blogging.
  3. Grinspoon, S. et al. (1 July 1998), "Effects of Androgen Administration in Men with the AIDS Wasting Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial", Annals of Internal Medicine 129 (1): 18-26
  4. Miller, K. et al. (August 1983), "Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study", Journal of Clinical Endocrinology & Metabolism 83 (8): 2717-2725